The chemical analysis device developer has added $20m to an initial public offering following $70m in funding from investors including Utec.
Bar-Ilan University’s textile developer Sonovia has completed an $18.5m initial public offering on the Tel Aviv Stock Exchange.
UTokyo Innovation Platform has scored an exit as the online investment platform developer went public on the Tokyo Stock Exchange.
The UBC-linked antibody drug developer has added $73m to its initial public offering, and its shares are still trading at more than double the IPO price.
Shares in the antibody discovery platform developer, advancing UBC research, opened at more than three times their IPO price to net it a valuation topping $15bn.
ETH Zurich-founded HeiQ chose the London Stock Exchange for its listing having posted a $10.9m operating profit for the first half of the year.
Berkeley Catalyst Fund-backed gene therapy developer 4D Molecular Therapeutics withdrew its last attempt in July.
Chronic illness drug developer Sigilon Therapeutics, co-founded by MIT and UIC researchers, has filed to go public after raising almost $200m in funding.